IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Management Quoted in “HIGH TIMES” Article

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced the publication of “Marijuana Could Help Treat Alzheimer’s: Here’s How It Would Work” on August 1, 2017, by Javier Hasse on the website of “HIGH TIMES,” a publication that’s served as the preeminent source for cannabis information since 1974. In the article, both Ram Mukunda, CEO of IGC, and Dr. Chuanhai Cao, the company’s key advisor, were quoted with respect to the potential therapeutic effects of THC on Alzheimer’s disease, which is noted as America’s most expensive ailment. “In Alzheimer’s Disease, beta-amyloid aggregates into a plaque-like substance that builds around the neurons and disrupts communication between them,” Mukunda stated in the publication. “So of course, if low-doses of THC can break up those plaques and prevent them from forming in the first place, it’s a huge breakthrough.” The full article is available for review at http://nnw.fm/5rWYd.

To view the full press release, visit http://nnw.fm/6bTyZ

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us